Summary
In a double blind cross-over study of 11 patients suffering from advanced chronic renal failure, the diuretic effect of single oral dose of muzolimine 240 mg and furosemide 240 mg was compared. The patients were stratified according to a serum creatinine of approximately 4/8 and 12 mg/dl, or a mean endogenous creatinine clearance of 21.7 ml/min/1.73 m2, 8.2 ml/min/1.73 m2 and 5.4 ml/min/1.73 m2. Urine volume and sodium excretion were studied biometrically using a 3-factor variance analysis. Urine excretion in all groups tended to be greater after muzolimine than after furosemide. The cumulative sodium excretion after muzolimine was significantly greater. In the groups with a creatinine clearance of 8.2 or 5.4 ml/min/1.73 m2, the duration of the time- response curve of muzolimine was greater than that of furosemide. Thus, even in advanced renal insufficiency, both substances had a saluretic effect. Muzolimine appeared to be significantly more effective than furosemide in causing natriuresis in patients with a serum creatinine of 4 to 8 mg/dl.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Reubi, F.C.: Clinical use of furosemide. Ann. N.Y. Acad. Sci.139, 433–442 (1966)
Heidland, A., Klütsch, K., Moormann, A., Hennemann, H.: Möglichkeiten und Grenzen hochdosierter Diuretikatherapie bei hydropischer Niereninsuffizienz. Dtsch. med. Wochenschr.94, 1568–1574 (1969)
Alison, M., Kennedy, A.C.: Diuretics in chronic renal disease. Clin. Sci.41, 171–187 (1971)
Goldberg, M.: The renal physiology of diuretics. In: Handbook of Physiology, Sect. 8: Renal Physiology, pp. 1003–1031. Baltimore: Williams and Wilkins 1973
Berg, K.J., Tromsdal, A., Widerøe, T.E.: Diuretic action of bumetanide in advanced chronic renal insufficiency. Europ. J. clin. Pharmacol.9, 265–275 (1976)
Möller, E., Horstmann, H., Meng, K., Loew, D.: 3-Amino-1-(3,4-dichloro-α-methyl-benzyl)-2-pyrazolin-5-one (BAY g 2821), a potent diuretic from a new substance class. Experientia33, 382–383 (1977)
Loew, D., Meng, K.: The renal mechanism of BAY g 2821. Pharmatherapeutica1, 333–340 (1977)
Meng, K., Loew, D., Stoepel, K., Hoffmeister, F.: Pharmacology of BAY g 2821, a long-acting, high-ceiling diuretic. Curr. Med. Res. Opin.4, 555–563 (1977)
Berg, K.H.: Jørstadt, S., Tromsdal, A.: Studies on the clinical pharmacology of a new potent diuretic, BAY g 2821. Pharmatherap.1, 319–332 (1976)
Hoppe-Seyler, G., Heissler, A., Cöppencastrop, M., Schindler, M., Schollmeyer, P., Ritter, W.: Investigations on the effect of a new diuretic BAY g 2821 in patients suffering from kidney diseases. Pharmatherapeutica1, 422–429 (1977)
Röckel, A.: Diuretic effects of BAY g 2821 in patients with advanced renal failure. Curr. Med. Res. Opin.4, 574–579 (1977)
Schmidt, P., Deutsch, E., Kriehuber, J.: Diät für chronisch Nierenkranke. Berlin, Heidelberg, New York: Springer 1973
Cochran, W.G., Cox, G.M.: Experimental design 2nd edit. London: Wiley 1957
Loew, D.: Diuretic action of BAY g 2821 in oedema-free volunteers. Curr. Med. Res. Opin.4, 455–461 (1976)
Quirin, H., Schaeffer, G., Kluthe, R.: Untersuchungen zur Harnstoffausscheidung bei Patienten mit fortgeschrittener chronischer Niereninsuffizienz und forcierter Diurese. Dtsch. med. Wochenschr.101, 923–927 (1976)
Endres, P., Kley, R., Heintz, R.: Die Wirkung einer akuten Diuresesteigerung auf Harnstoff- und Kreatinin-Clearance bei Gesunden und bei Patienten mit chronischer Niereninsuffizienz. Klin. Wochenschr.53, 575–578 (1975)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schmidt, P., Loew, D., Dýcka, J. et al. Comparison of the pharmacodynamic effect of muzolimine and furosemide in patients with advanced chronic renal insufficiency. Eur J Clin Pharmacol 14, 399–403 (1978). https://doi.org/10.1007/BF00716380
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00716380